InventisBio Co Ltd Class A 688382
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥8.42
- Day Range
- ¥9.08–9.88
- 52-Week Range
- ¥6.50–18.41
- Bid/Ask
- ¥9.79 / ¥9.80
- Market Cap
- ¥5.65 Bil
- Volume/Avg
- 13.0 Mil / 4.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 47.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 222
- Website
- http://www.inventisbio.com
Comparables
Valuation
|
Metric
|
688382
|
02480
|
IMU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.11 | 4.61 | 2.97 |
Price/Sales | 47.15 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
688382
02480
IMU
Financial Strength
|
Metric
|
688382
|
02480
|
IMU
|
|---|---|---|---|
Quick Ratio | 12.67 | 5.91 | 3.66 |
Current Ratio | 12.74 | 5.97 | 3.86 |
Interest Coverage | — | −333.17 | −321.34 |
Quick Ratio
688382
02480
IMU
Profitability
|
Metric
|
688382
|
02480
|
IMU
|
|---|---|---|---|
Return on Assets (Normalized) | −15.88% | −24.42% | −67.09% |
Return on Equity (Normalized) | −17.08% | −27.57% | −77.26% |
Return on Invested Capital (Normalized) | −18.99% | −27.46% | −79.58% |
Return on Assets
688382
02480
IMU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nhzggyhgww | Src | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mphldglxp | Rvdlk | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gfmzwnvpx | Dfhyky | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zbykhyml | Cmjqdj | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Kmpvmptzr | Qmy | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Tzqtnth | Kqlh | $29.2 Bil | |||
| Moderna Inc
MRNA
| Fksnbgtnx | Zfysy | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tkydzbz | Lmms | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Knjscmlxp | Jhdxsf | $13.2 Bil | |||
| Incyte Corp
INCY
| Tlzbrmgw | Rgcgzq | $13.0 Bil |
United States